Acknowledgements
The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information S1 (box)
Definitions and data analysis (PDF 140 kb)
Supplementary information S2 (table)
Summary of MAA submissions, SA requests and compliance with SA by year (PDF 107 kb)
Supplementary information S3 (table)
MAA procedure time and the number of MOs in relation to compliance with SA on clinical trial design (PDF 97 kb)
PowerPoint slides
Rights and permissions
About this article
Cite this article
Hofer, M., Jakobsson, C., Zafiropoulos, N. et al. Impact of scientific advice from the European Medicines Agency. Nat Rev Drug Discov 14, 302–303 (2015). https://doi.org/10.1038/nrd4621
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4621
- Springer Nature Limited
This article is cited by
-
How to START? Four pillars to optimally begin your orphan drug development
Orphanet Journal of Rare Diseases (2023)
-
Innovationsunterstützung im BfArM – Erfahrungen aus den Beratungen zu digitalen Gesundheitsanwendungen (DiGA)
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz (2021)
-
Oncology Products in the European Union: An Analysis of Regulatory Approvals with a CHMP Oral Explanation
Therapeutic Innovation & Regulatory Science (2021)
-
Regulatory responses to assisted reproductive technology: a comparative analysis of Spain and Israel
Journal of Assisted Reproduction and Genetics (2019)
-
Scientific advice — is drug repurposing missing a trick?
Nature Reviews Clinical Oncology (2017)